4.8 Editorial Material

Singles Engage the RNA Interference Pathway

Journal

CELL
Volume 150, Issue 5, Pages 873-875

Publisher

CELL PRESS
DOI: 10.1016/j.cell.2012.08.008

Keywords

-

Funding

  1. NINDS NIH HHS [P01NS050210, RC1 NS068280] Funding Source: Medline

Ask authors/readers for more resources

Single-stranded RNAs interact with components of the RNA interference pathway to reduce the expression of target mRNAs. Now, Lima et al. and Yu et al. show that, with extensive chemical modifications, small single-stranded RNAs can robustly induce gene silencing with efficacy similar to their double-stranded counterparts.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biotechnology & Applied Microbiology

AAV-Mediated Progranulin Delivery to a Mouse Model of Progranulin Deficiency Causes T Cell-Mediated Toxicity

Defne A. Amado, Julianne M. Rieders, Fortunay Diatta, Pilar Hernandez-Con, Adina Singer, Jordan T. Mak, Junxian Zhang, Eric Lancaster, Beverly L. Davidson, Alice S. Chen-Plotkin

MOLECULAR THERAPY (2019)

Article Cell & Tissue Engineering

Generation of Spinocerebellar Ataxia Type 2 induced pluripotent stem cell lines, CHOPi002-A and CHOPi003-A, from patients with abnormal CAG repeats in the coding region of the ATXN2 gene

Jean Ann Maguire, Alyssa L. Gagne, Pedro Gonzalez-Alegre, Beverly L. Davidson, Vikram Shakkottai, Paul Gadue, Deborah L. French

STEM CELL RESEARCH (2019)

Editorial Material Biotechnology & Applied Microbiology

Doubling down on siRNAs in the brain

Beverly L. Davidson

NATURE BIOTECHNOLOGY (2019)

Review Biotechnology & Applied Microbiology

Gene therapy for ALS: A review

Defne A. Amado, Beverly L. Davidson

Summary: ALS has historically been challenging for gene therapy due to a lack of therapeutic targets and difficulty accessing the brain and spinal cord. Recent advances in disease mechanism understanding, ALS genetics, and CNS targeting, along with progress in gene delivery and editing techniques, have opened new therapeutic possibilities. Gene therapy clinical trials are underway for ALS patients with various genetic mutations, showing potential for disease-modifying treatment.

MOLECULAR THERAPY (2021)

Review Biotechnology & Applied Microbiology

Next-generation strategies for gene-targeted therapies of central nervous system disorders: A workshop summary

Jill A. Morris, Chris H. Boshoff, Nina F. Schor, Ling M. Wong, Guangping Gao, Beverly L. Davidson

Summary: NINDS organized a workshop on gene-targeted therapies for CNS disorders, bringing together experts from various fields to identify challenges and propose solutions. Prior to the workshop, key obstacles and research gaps were identified through pre-meeting teleconferences, allowing for problem-solving discussions and strategy development at the workshop.

MOLECULAR THERAPY (2021)

Letter Biotechnology & Applied Microbiology

Limited astrocyte-to-neuron conversion in the mouse brain using NeuroD1 overexpression

David Leib, Yong Hong Chen, Alex Mas Monteys, Beverly L. Davision

MOLECULAR THERAPY (2022)

Correction Multidisciplinary Sciences

Regulated control of gene therapies by drug-induced splicing (February, 10.1038/s41586-021-03770-2, 2022)

Alex Mas Monteys, Amiel A. Hundley, Paul T. Ranum, Luis Tecedor, Amy Muehlmatt, Euyn Lim, Dmitriy Lukashev, Rajeev Sivasankaran, Beverly L. Davidson

NATURE (2022)

Review Biotechnology & Applied Microbiology

Gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders

Beverly L. Davidson, Guangping Gao, Elizabeth Berry-Kravis, Allison M. Bradbury, Carsten Bonnemann, Joseph D. Buxbaum, Gavin R. Corcoran, Steven J. Gray, Heather Gray-Edwards, Robin J. Kleiman, Adam J. Shaywitz, Dan Wang, Huda Y. Zoghbi, Terence R. Flotte, Sitra Tauscher-Wisniewski, Cynthia J. Tifft, Mustafa Sahin

Summary: The review summarizes the discussions and presentations of a workshop sponsored by the National Institute of Mental Health, focusing on gene-based therapeutics for rare genetic neurodevelopmental psychiatric disorders. It highlights the potential of precision medicine approaches in treating these disorders.

MOLECULAR THERAPY (2022)

Article Medicine, Research & Experimental

Combined overexpression of ATXN1L and mutant ATXN1 knockdown by MV rescue motor phenotypes and gene signatures in SCA1 mice

Ellie M. Carrell, Megan S. Keiser, Ashley B. Robbins, Beverly L. Davidson

Summary: The study shows that targeting ATXN1 through RNA interference and overexpression of ATXN1L can prevent and reverse disease phenotypes in SCA1 mice. Combination of these therapeutic approaches leads to more effective SCA1 therapy.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)

Article Multidisciplinary Sciences

Huntington's disease phenotypes are improved via mTORC1 modulation by small molecule therapy

Sophie St-Cyr, Daniel D. Child, Emilie Giaime, Alicia R. Smith, Christine J. Pascua, Seung Hahm, Eddine Saiah, Beverly L. Davidson

Summary: A novel small molecule mTORC1 pathway activator, NV-5297, has been found to improve disease phenotypes in a mouse model of Huntington's Disease, including increased striatal volume, improved motor learning, and heart contractility.

PLOS ONE (2022)

Article Biotechnology & Applied Microbiology

Targeted long-read sequencing captures CRISPR editing and AAV integration outcomes in brain

Bryan P. Simpson, Carolyn M. Yrigollen, Aleksandar Izda, Beverly L. Davidson

Summary: Using polymerase-free, targeted long-read nanopore sequencing, we evaluated the editing effects of single and dual gRNA AAV-CRISPR on the human ATXN2 gene in transgenic mouse models of SCA2. The results showed an editing rate of 10%-25% and identified AAV integration, large deletions, and transgene rearrangements as unexpected outcomes. PCR-based nanopore sequencing, in contrast, showed a bias for partial AAV fragments and inverted terminal repeats and failed to detect full-length AAV. This study provides a comprehensive understanding of the outcome spectrum of CRISPR editing in the mouse brain after AAV gene transfer using an unbiased long-read sequencing approach.

MOLECULAR THERAPY (2023)

Letter Biotechnology & Applied Microbiology

Cochlear transduction via cerebrospinal fluid delivery of AAV in non-human primates

Paul T. Ranum, Luis Tecedor, Megan S. Keiser, Yong Hong Chen, David E. Leib, Xueyuan Liu, Beverly L. Davidson

MOLECULAR THERAPY (2023)

Article Multidisciplinary Sciences

Regulated control of gene therapies by drug-induced splicing

Alex Mas Monteys, Amiel A. Hundley, Paul T. Ranum, Luis Tecedor, Amy Muehlmatt, Euyn Lim, Dmitriy Lukashev, Rajeev Sivasankaran, Beverly L. Davidson

Summary: A universal switch element has been developed for precise control of gene replacement or editing machinery after exposure to small molecules. This switch system, called X-on, allows controlled protein expression by adjusting drug dose, protein stability, and redosing. It offers an opportunity to refine and tailor gene therapies in humans due to its oral bioavailability and safety of the drugs used.

NATURE (2021)

Article Medicine, Research & Experimental

Neuronal network dysfunction precedes storage and neurodegeneration in a lysosomal storage disorder

Rebecca C. Ahrens-Nicklas, Luis Tecedor, Arron F. Hall, Elena Lysenko, Akiva S. Cohen, Beverly L. Davidson, Eric D. Marsh

JCI INSIGHT (2019)

Review Neurosciences

CRISPR to the Rescue: Advances in Gene Editing for the FMR1 Gene

Carolyn M. Yrigollen, Beverly L. Davidson

BRAIN SCIENCES (2019)

No Data Available